Latest Headlines

Latest Headlines

Celsion shares routed after PhIII liver cancer study flops

Celsion was the center of a considerable amount of market buzz over the last year as the small biotech pushed a late-stage cancer drug through a Phase III liver cancer study. Its stock price tripled as investors rode a swell of enthusiasm that Celsion could beat the tough odds that face any small-cap company trying to make it all the way through an oncology program.

Celsion snags up to $100M Chinese pharma tie-up ahead of PhIII cancer data

Celsion ($CLSN) grabbed $5 million in a development deal with China's Zhejiang Hisun Pharmaceutical, which has shown interest in advancing Celsion's ThermoDox product in China, Hong Kong and Macau.

ThermoDox a step away from orphan approval in Europe

Celsion ($CLSN), a drug-development company based in Columbia, MD, has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency has issued a positive opinion

Heat-activated liposomes attracts SBIR grant

Celsion, a drug-development company based in Columbia, MD, has been awarded a $200,000 Phase I SBIR grant from the NIH for its low heat-activated liposomes, which the company says enables delivery of

Celsion's ThermoDox liver cancer trials get fast-tracked

Drug developer Celsion and sufferers of primary liver cancer received some good news from the FDA this week as the Columbia, MD-based company's first drug, ThermoDox, was granted fast-track status.